Your session is about to expire
← Back to Search
Senolytic Therapy for Chronic Kidney Disease
Study Summary
This trial will test whether getting rid of senescent cells can help people with chronic kidney disease by reducing senescence burden, improving physical ability or frailty, and increasing mesenchymal stem cell functionality.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function is reduced, with an eGFR between 15-45.Your total bilirubin level is more than twice the normal limit.I have a new cancer diagnosis that is not a non-melanoma skin cancer.I cannot take medications by mouth.I am currently on medication to suppress my immune system.My weight is over 150 kg or my BMI is over 50.I am not willing to stop my acid reflux medication for 3 weeks.My lupus is not under control.I have unmanaged fluid buildup in my chest or abdomen.I am taking blood thinners or antiplatelet drugs and cannot stop them for the trial.I am HIV positive.I am unable to understand and give consent for treatment.I am on a medication that targets cancer growth.I have taken quinolone antibiotics in the last 10 days.You drink more than 3 alcoholic drinks a day or more than 21 drinks a week.I am taking medication that strongly affects liver enzyme CYP3A4.I do not have an active hepatitis B or C infection.I have diabetes and am on medication for it.Your heart's QT interval is longer than 450 milliseconds.You are allergic to dasatinib or quercetin.I have a kidney condition called glomerulonephritis.I have an invasive fungal or viral infection.You have had problems with drugs or alcohol in the last 2 years.I have been diagnosed with kidney artery disease.I have a genetic form of polycystic kidney disease.Your hemoglobin A1c level is 10% or higher during screening.I am not on medication that affects certain liver enzymes or only take them if necessary and monitored.I have been diagnosed with nephrotic syndrome.I have had a solid organ transplant.I am between 40 and 80 years old.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Group 1: Group 1: Observational
- Group 2: Group 2: Dasatinib & Quercetin
Frequently Asked Questions
Is there an opportunity to participate in this experimental research?
"Eligibility requirements for this trial state that individuals must have chronic kidney disease and be between 40-80 years of age. The study is planning to accept around 30 participants."
Are there any participants being accepted for this experiment at the moment?
"As per the clinicaltrials.gov page, this particular medical trial is not looking for new applicants at present. It was initially posted on July 1st 2016 and its last update happened on May 14th 2022. However, there are 564 other trials actively enrolling patients right now."
Is eligibility for this trial limited to those under the age of 70?
"This research is enrolling participants aged 40 years and above, with a cut-off at 80."
How risky is it to use the combination of dasatinib and quercetin?
"Group 2: Dasatinib & Quercetin has a safety rating of 2 due to the available data from Phase 2 trials, which indicate that it is safe but not yet proven effective."
What investigations have been performed on the combination of Dasatinib & Quercetin in Group 2?
"Currently, 9 trials of Group 2: Dasatinib & Quercetin are in Phase 3 and 68 total clinical studies exploring this combination. The majority of these occur in New york City; however, there are 4262 other places hosting investigations into the efficacy and safety of Group 2: Dasatinib & Quercetin."
What is the aggregate amount of participants involved in this investigation?
"Registration for this medical trial is no longer available. The first posting of the study was on July 1st 2016 and last updated May 14th 2022. If you are seeking other studies, there currently exists 496 clinical trials actively recruiting patients with chronic kidney diseases and 68 inquiries involving Dasatinib & Quercetin looking to expand their participant pool."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger